Boston Trust Walden’s Gilead Sciences GILD Stock Holding History

Boston Trust Walden’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,395	Closed	-$240K	–	376
2017 Q2	$240K	Buy	+3,395	New	+$226K	﹤0.01%	363

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Boston Trust Walden's GILD Position: Q3 2017 in Review

Boston Trust Walden sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 3,395 shares — an estimated $240K sold.

Boston Trust Walden first reported a position in GILD in Q2 2017 and held it in 1 quarter. The position peaked at $240K in Q2 2017. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

Boston Trust Walden reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
Boston Trust Walden sold 3,395 Gilead Sciences shares in Q3 2017, an estimated $240K.
Boston Trust Walden first reported a position in Gilead Sciences in Q2 2017 and held it in 1 quarter.
Boston Trust Walden's Gilead Sciences position peaked at $240K in Q2 2017.
1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Boston Trust Walden's 13F filing for Q3 2017, filed 13 Oct 2017.